Ireland
--:--IST
Recruiting Not applicable

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

NCT07395206 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2026-01-30
Last updated
2026-03-03

Condition(s) studied

PsychosisPsychotic DisordersPrimary Psychotic DisordersSchizophrenia Spectrum DisordersSchizophreniaSchizoaffective Disorder

Investigational drug(s) / intervention(s)

Digital: Kiso Mind App

Digital: Kiso Mind App: See above.

Study summary

The Kiso pilot study is a randomized controlled trial to test the acceptability and feasibility of a novel digital intervention, namely the Kiso Mind smartphone app. A parallel-group design is utilized. Participants either receive access to the Kiso Mind intervention and treatment-as-usual (TAU) in the experimental condition or receive treatment as usual (TAU) in the control condition. The intervention is designed for participants diagnosed with either schizophrenia (F20.0) or schizoaffective disorder (F25.0) according to the ICD-10.

To examine acceptability, feasibility, and preliminary effectiveness, both self-report and rater-based assessments are administered at baseline (T0) and at the end of the 12-week intervention period (post-intervention T1). Lastly, a qualitative interview will be conducted with participants from the experimental condition. The primary outcome of the present study is the acceptability and feasibility of the Kiso Mind app. The secondary outcome consists of general psychopathology, and positive-, negative-, depressive symptoms, as well as social functioning and self-efficacy ratings.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * ICD-10: F20 Schizophrenia, F25 Schizoaffective Disorder * Age: 18 - 65 years * Sufficient German Language Proficiency * Ability to Use a Smartphone Exclusion Criteria: * Intensive Psychotherapy Protocols (more than one psychotherapy session a month) * CGI-Score \< 3; \> 6 * No smartphone * Neurological Disorders or Brain Damage * Acute Suicidality * Acute Heavy Substance Abuse or Addiction * Current Electroconvulsive Therapy

Primary outcome measure(s)

  • Proportion of PP receiving threshold dose (Acceptability) — 12 weeks
    The proportion of modules completed on average by all participants.
  • Nr. of pp willing to participate (Feasibility) — 12 weeks
    The number of eligible participants, that are willing to participate in Kiso (recruitment)

Trial sites (1)

FacilityCityRegionStatus
Charité - Universitätsmedizin Berlin Berlin State of Berlin Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07395206 on ClinicalTrials.gov ↗ ← All trials in Germany